Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
Haematologica. 2018 Oct;103(10):1654-1661. doi: 10.3324/haematol.2018.189514. Epub 2018 Jul 5.
Haematologica. 2018.
PMID: 29976746
Free PMC article.
Clinical Trial.
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group.
Ferguson P, et al.
Haematologica. 2016 Nov;101(11):1351-1358. doi: 10.3324/haematol.2016.148825. Epub 2016 Aug 18.
Haematologica. 2016.
PMID: 27540133
Free PMC article.
Item in Clipboard
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.
Russell N, Burnett A, Hills R, Betteridge S, Dennis M, Jovanovic J, Dillon R, Grimwade D; NCRI AML Working Group.
Russell N, et al.
Blood. 2018 Sep 27;132(13):1452-1454. doi: 10.1182/blood-2018-05-851824. Epub 2018 Aug 10.
Blood. 2018.
PMID: 30097508
Free PMC article.
Clinical Trial.
No abstract available.
Item in Clipboard
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH.
Othman J, et al.
Blood Adv. 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276.
Blood Adv. 2023.
PMID: 37171402
Free PMC article.
Clinical Trial.
Item in Clipboard
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group.
Russell NH, et al.
J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12.
J Clin Oncol. 2024.
PMID: 38215358
Clinical Trial.
Item in Clipboard
Nocebo effects and participant information leaflets: evaluating information provided on adverse effects in UK clinical trials.
Kirby N, Shepherd V, Howick J, Betteridge S, Hood K.
Kirby N, et al.
Trials. 2020 Jul 17;21(1):658. doi: 10.1186/s13063-020-04591-w.
Trials. 2020.
PMID: 32680561
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite